Pfizer Independent Medical Education Grant Request for Proposals: Advancing Adult Immunization Strategies – A Focus on the Impact of Respiratory Syncytial Virus (RSV) and Cardiorespiratory Outcomes
Pfizer funds educational projects to improve adult RSV immunization and integrate RSV prevention into cardiovascular care, focusing on the virus's impact on heart and lung health.
Funder: Pfizer Inc.
Due Dates: June 30, 2026 (full proposal due via CyberGrants, 23:59 EST)
Funding Amounts: Up to $200,000 per project; total available budget is $200,000; project duration up to 12 months
Summary: Supports independent medical education projects that advance adult RSV immunization strategies, with emphasis on cardiorespiratory outcomes and integration into cardiovascular care.
Key Information: Organizations only (not individuals); projects must be non-clinical education initiatives focused on healthcare professionals in the United States.
Description
This grant opportunity from Pfizer Inc. supports independent medical education initiatives aimed at improving adult immunization strategies against respiratory syncytial virus (RSV), focusing on the virus’s impact on cardiorespiratory outcomes and the integration of prevention into cardiovascular care. The program seeks to address gaps in clinician awareness and practice by funding educational projects that highlight the epidemiology and burden of RSV, its association with cardiovascular morbidity and mortality, emerging evidence on RSV vaccination, and current immunization recommendations. The ultimate goal is to enhance healthcare professionals’ understanding of RSV prevention as an integral part of managing cardiovascular disease in adults.
